Galenica AG earnings date
Want to see CH:GALE full AI Analyst Report?
Galenica AG (GALE) Q2 2026 Earnings Report
CH:GALE Q2 2026 EPS Results
- Actual EPS
- CHF 1.83
- Consensus EPS
- CHF 1.93
- Beat/Miss
- Missed by -CHF 0.10
- One Year Ago EPS
- CHF 1.81
CH:GALE Q2 2026 Revenue Results
- Actual Revenue
- CHF 2.14B
- Expected Revenue
- CHF 2.13B
- Beat/Miss
- Beat by +CHF 6.73M
- YoY Revenue Growth
- +7.07%
Earnings Announcement Details
- Quarter
- Q2 2026
- Date
- 08/06/2026
- Time
- TBA
- Conference Call
- Thursday, August 6, 2026
Galenica AG's next earnings date is estimated for March 9, 2027, based on past reporting schedules.
Q2 2026 Earnings Call Audio
No earnings call audio is available for this earnings event.
Q2 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q2 2026 Earnings Call Summary
The call presented solid operational momentum: double-digit adjusted EBIT growth (adjusted), strong retail and services performance, successful integration steps (Labor Team, homecare consolidation), and reaffirmation of full-year guidance. Headwinds are mostly seasonal or transitional (weak cold/flu season, Perskindol stock adjustments, Bichsel restructuring costs, temporary working capital and ERP-related effects) and largely framed as manageable by management. Regulatory changes and long-term liberalization of mail-order OTC present risks but are expected to be gradual. On balance, positives (broad sales and profit growth, service adoption, automation gains, and guidance confirmation) outweigh the negatives.
Galenica reaffirmed its 2026 guidance for consolidated net sales growth of 5.7% and EBIT growth of 6–8%, with a stable dividend at least at prior-year level, supported by strong H1 results: sales +7.1% to CHF 2.136bn and adjusted EBIT +7.1% to just under CHF 118m (12.6% EBIT growth adjusted for prior-year one‑offs); adjusted net debt stood at CHF 837m (leverage 2.7x, targeting 2.2–2.3x at year‑end). The company noted segment and operational metrics that underpin the guidance: group growth excl. Labor Team (which contributed 3.1%) was 4.0%, Products & Care +11.5%, Logistics & IT +4.2%, Services & Production +9.4% to CHF 63.4m, local pharmacies +6.2% (organic +4.3%, net +3 locations = +1.9% incl. Puravita), wholesale +4.3% (pharmacy channel +6.3%), market H1 growth 3.7% (brick‑and‑mortar +5.4%, physicians +3.1%, volumes −0.6%). Operational and strategic datapoints included 193,000 fee‑paying consultations (+27% YoY), ~90,000 Prescription Manager users, 25,000 vaccinations in H1, >1 million policyholders with insurance coverage for services, GLP‑1s growing ~30% (≈4% of pharmacy sales, ~1% of group sales), Ecublens automation ~70%, capex guidance CHF 80–90m for 2026, Bichsel one‑off restructuring costs ~CHF 30m, and an expected liberalization of mail‑order OTC not before 2029/2030 potentially affecting up to ~13% of pharmacy‑related sales.
- Strong Top-Line GrowthGroup sales increased 7.1% to CHF 2.136 billion in H1 2026. Adjusted for the Labor Team acquisition (which contributed 3.1%), organic group growth was 4.0%.
- EBIT and Adjusted Profitability ExpansionAdjusted EBIT rose 7.1% to just under CHF 118 million; excluding prior-year one-offs this corresponds to an adjusted EBIT growth of 12.6%. Profitability in Products & Care improved from 9.3% to 9.6%.
- Confirmation of Full-Year Guidance and Dividend PolicyManagement reaffirmed 2026 guidance of consolidated net sales growth of 5.7% and EBIT growth between 6% and 8%, and confirmed a stable dividend strategy (at least at prior-year level).
- Strong Retail & Pharmacy MomentumBrick-and-mortar pharmacy market grew 5.4% (prescription medicines +6.9%). Galenica's local pharmacies grew 6.2% (organic growth 4.3%) and the network expanded by a net 3 locations; acquisition of Puravita added ~1.9% to sales.
- Healthcare Services and Patient Engagement GrowthFee-paying healthcare consultations reached 193,000 in H1 (+27% YoY). The Prescription Manager reached ~90,000 users by mid-year. Over 1 million Swiss policyholders have insurance coverage for Galenica services; pharmacies administered 25,000 vaccinations in H1.
- Services, Homecare and Integration WinsServices & Production sales rose 9.4% to CHF 63.4 million, driven by homecare (Bichsel, Lifestage, Medifilm). Bichsel HomeCare and Lifestage were fully merged to create a single homecare offering; Medifilm patient base is growing and machinery upgrades are automating processes.
- Operational Automation and Efficiency ProgressLausanne-Ecublens site automation now ~70%, improving capacity utilization. Niederbipp to switch to SAP (end-Aug/early Sept) with expected 2027 efficiency gains. Labor Team integration progressing with new automated microbiology line at Goldach.
- Lower-than-Expected Restructuring ChargeExtraordinary costs related to winding down Bichsel pharmaceutical production were CHF ~30.4 million in H1, lower than the originally expected CHF 35–40 million range.
CH:GALE Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Mar 09, 2027 | 2026 (Q4) | 1.99- | 1.86 | ― | ― |
| Aug 06, 2026 | 2026 (Q2) | 1.931.83 | 1.81 | 1.10% (+0.02) | |
| Mar 10, 2026 | 2025 (Q4) | 1.991.86 | 2.09 | -10.78% (-0.23) | |
| Aug 07, 2025 | 2025 (Q2) | 1.751.81 | 1.55 | 16.77% (+0.26) | |
| Mar 11, 2025 | 2024 (Q4) | 1.832.09 | 1.97 | 5.78% (+0.11) | |
| Aug 06, 2024 | 2024 (Q2) | 1.691.55 | 1.49 | 4.03% (+0.06) | |
| Mar 12, 2024 | 2023 (Q4) | 1.661.97 | 1.69 | 16.80% (+0.28) | |
| Aug 08, 2023 | 2023 (Q2) | 1.551.49 | 1.63 | -8.59% (-0.14) | |
| Mar 07, 2023 | 2022 (Q4) | 1.621.69 | 1.86 | -9.14% (-0.17) | |
| Aug 09, 2022 | 2022 (Q2) | 1.321.63 | 1.66 | -1.81% (-0.03) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

